Search
Tertomotide
go.drugbank.com/drugs/DB12747InvestigationalIt is being developed by Pharmexa A/S. … Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma).
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.
Seliciclib
go.drugbank.com/drugs/DB06195InvestigationalDeveloped by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation … R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated
Raltitrexed
go.drugbank.com/drugs/DB00293ApprovedInvestigationalRaltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
Methoxyphenamine
go.drugbank.com/drugs/DB13624ApprovedCategories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesMebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnIt was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.
PH-284
go.drugbank.com/drugs/DB05452ExperimentalPH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.
Oglufanide
go.drugbank.com/drugs/DB05779InvestigationalOglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection. … Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.
Categories: Compounds used in a research, industrial, or household settingJNJ-17216498
go.drugbank.com/drugs/DB17087InvestigationalJNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]